Natera (NTRA) to Release Quarterly Earnings on Wednesday

Natera (NASDAQ:NTRA) will be issuing its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.57) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, May 9th. The medical research company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.05. Natera had a negative return on equity of 699.31% and a negative net margin of 49.33%. The business had revenue of $66.82 million for the quarter, compared to analyst estimates of $66.40 million. On average, analysts expect Natera to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ NTRA traded down $0.57 during midday trading on Monday, hitting $27.12. 8,330 shares of the company’s stock were exchanged, compared to its average volume of 443,165. The company has a debt-to-equity ratio of 20.88, a quick ratio of 1.73 and a current ratio of 1.85. Natera has a twelve month low of $11.08 and a twelve month high of $29.62. The company has a market cap of $1.88 billion, a P/E ratio of -12.57 and a beta of 1.51. The firm has a fifty day simple moving average of $26.20.

Several equities research analysts have recently weighed in on NTRA shares. Zacks Investment Research lowered Natera from a “hold” rating to a “sell” rating in a research report on Wednesday, July 17th. Canaccord Genuity raised their target price on Natera from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. BidaskClub raised Natera from a “sell” rating to a “hold” rating in a research report on Wednesday, June 12th. Finally, Piper Jaffray Companies raised their target price on Natera from $23.00 to $28.00 and gave the stock an “overweight” rating in a research report on Monday, June 10th. One analyst has rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Natera presently has a consensus rating of “Buy” and a consensus price target of $30.14.

In other Natera news, insider Jonathan Sheena sold 1,033 shares of Natera stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $24.79, for a total transaction of $25,608.07. Following the transaction, the insider now owns 240,061 shares of the company’s stock, valued at $5,951,112.19. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Chairman Matthew Rabinowitz sold 1,418 shares of Natera stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $24.79, for a total value of $35,152.22. Following the transaction, the chairman now directly owns 1,286,612 shares in the company, valued at approximately $31,895,111.48. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,311 shares of company stock worth $132,287. 9.29% of the stock is currently owned by corporate insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also: Economic Reports

Earnings History for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.